A mid-stage trial of BPL‑003 nasal spray shows promising results for treatment-resistant depression, igniting biotech ...

A nasal spray for treatment-resistant depression has delivered strong clinical results and rekindled investor hopes.

A panelist discusses how a prospective study demonstrated that twice-daily use of a nasal spray significantly improved tear ...

Positive data on depression treatment based on a drug related to the psychedelic DMT is breathing life into shares of ...

Positive study results in Phase 2 lead to a green light for the companies’ combination and plans to move their nasal spray ...

The companies are also running an open-label study to evaluate the long-term efficacy and safety of the psychedelic in ...

BPL-003 showed “robust” efficacy data in treatment-resistant depression, according to analysts from Jefferies, who noted that ...

A psychedelic nasal spray requiring a much shorter period of clinical supervision has shown promise against ...

Zolmitriptan has previously been shown to appear in plasma as early as 5 minutes after administration. [3, 4] The nasal spray also demonstrates a very fast onset of action, with high and sustained ...

Esketamine, a form of ketamine taken as a nasal spray, has been approved for the treatment for moderate to severe ...

A new study investigates how ketamine infusion affects different parts of the brain and could be an effective pharmaceutical solution to treat depression.

SAN FRANCISCO — Both dyspnea and respiratory drive went down with vs. without nasal high-flow therapy in orally intubated patients, according to research presented at the American Thoracic ...